AFFILIATIONS
1 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
2 EBMT LWP Paris Office, Hôpital Saint-Antoine, Paris, France
3 EBMT LWP Paris Office, Hôpital Saint-Antoine, Paris, France
4 Department of Haematology, University College London Hospital and London North West University Heathcare NHS Trust, London, United Kingdom
5 Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain
6 Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7 University College London Hospitals NHS Trust, London, United Kingdom
8 Aix-Marseille Univ, MSC Lab, Department of Hematology, Institut Paoli-Calmettes, Marseille, France
9 Transplantation Unit Department of Oncology and Haematology, IRCCS Humanitas Research Hospital, Milan, Italy
10 University Hospitals Bristol and Weston NHSFT, Bristol, United Kingdom
11 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
12 Medical Clinic, Charité University Medicine Berlin, Berlin, Germany
13 Division of Hematology, Città della Salute e della Scienza Hospital and University, Turin, Italy
14 Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Milan, Italy
15 Department of Hematology, Jean Minjoz University Hospital, Besancon, France
16 Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy
17 Azienda Ospedaliero Universitaria di Udine, Udine, Italy
18 University of Leipzig Medical Center, Department for Hematology, Cellular Therapies and Hemostaseology, Leipzig, Germany
19 Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
20 Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany
21 Department of Hematology, University Medical Center Groningen, Rijksuniversiteit Groningen, Groningen, Netherlands
22 Helios Hospital Berlin-Buch, Department of Hematology and Cell Therapy, Berlin, Germany
23 Hematology, Southampton General Hospital, Southampton, United Kingdom
24 Universitätsklinikum Bochum – Knappschaft Kliniken, Ruhr-University Bochum, Bochum, Germany
25 Unit of Hematology and Hematopoietic Stem Cell Transplantation, Fondazione Policlinico Universitario A. Gemelli IRCCS Roma, Rome, Italy
26 Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany
27 Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany
28 Department of Adult Hematology, Necker Hospital, Imagine Institute, Université De Paris-cité, Assistance Publique Des Hôpitaux De Paris, Paris, France
29 Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
30 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
ABSTRACT
Introduction:
The introduction of the CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) brexucel has revolutionized the therapeutic landscape for r/r MCL. However, patients with prior allogeneic hematopoietic stem cell transplantation (alloHCT) were excluded from the ZUMA-2 approval trial, and real-world analyses are not yet available to allow conclusions on this subset. On the other hand, the majority of brexucel recipients experience MCL recurrence, mandating effective salvage options in this otherwise very dismal setting. Currently, there is little known about the outcome of alloHCT used as a rescue option for post-CAR-T MCL relapse.
Methods:
The inclusion criteria for this 2-part registry study were defined as follows: Age ≥18 years and r/r MCL with either (Part AB) a first brexucel therapy between 2016 and 2025 after prior alloHCT; or (Part BA) a first alloHCT between 2016 and 2025 after prior brexucel treatment. Outcome data were extracted from the European Society for Blood and Marrow Transplantation (EBMT) registry database. Primary endpoint was progression-free survival (PFS) measured from second cellular therapy (CT; CAR-T and alloHCT, respectively). Secondary endpoints were overall survival (OS), non-relapse mortality (NRM), incidence of relapse/progression (RI) from second CT; and causes of death.
Results:
Part AB: 44 patients receiving brexucel after prior alloHCT were eligible for this study. Their median age at brexucel administration was 62 years (range 57-66) and the majority were male (82%). 27 of 44 patients (61%) showed non-responsive disease (no complete or partial remission) to bridging therapy at lymphodepletion. The time interval between the alloHCT and brexucel was 47 months (range 29-62). A wide variety of conditioning regimens had been used for the prior alloHCT, primarily fludarabine-based and reduced-intensity. After a median follow-up of two years (range 1.1-3.1), OS, PFS, RI, and NRM at two years after brexucel was 66%, 61%, 27% and 12%, respectively. 14 patients died (7 (16%) due to MCL and 7 (16%) to non-relapse causes).
Part BA: 34 patients received an alloHCT after prior brexucel and were eligible for this study. Their median age at second CT was 57 years (range 53-65) and the majority of patients included were also male (82%). Compared to part AB, there were no new aspects regarding alloHCT conditioning regimens. 17 of 34 patients (50%) showed non-responsive disease before alloHCT. The median time to relapse after brexucel had been 7.1 months (range 3.0-11.9). After a median follow-up of one year (range 0.3-2.1), OS, PFS, RI, and NRM one year after alloHCT was 53%, 49%, 36%, and 16%, respectively. Cause of death was MCL progression in 7 (21%) and NRM in 4 (12%) patients.
Conclusions:
With survival outcomes similar to alloHCT-naïve patients (PMID 40229536), prior alloHCT does not seem to adversely affect brexucel efficacy and safety. Vice versa, alloHCT seems to be a promising approach after brexucel failure in transplant-eligible patients, given the poor prognosis of this patient subset with non-transplant strategies (PMID 40763269).